Heart failure—the importance of ethnicity

[1]  J. Cleland.  Letter from the outgoing Editor‐in‐Chief of the European Journal of Heart Failure , 2005 .

[2]  M. Domanski,et al.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.

[3]  S. Dunlap,et al.  Survival rates are similar between African American and white patients with heart failure. , 2003, American heart journal.

[4]  N. Chaturvedi.  ETHNIC DIFFERENCES IN CARDIOVASCULAR DISEASE , 2003, Heart.

[5]  H. Krumholz,et al.  Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. , 2003, JAMA.

[6]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[7]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[8]  S. Oparil,et al.  Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. , 2003, Journal of the American College of Cardiology.

[9]  P. Mills,et al.  Bangladeshi patients present with non-classic features of acute myocardial infarction and are treated less aggressively in east London, UK , 2003, Heart.

[10]  Jun Ren,et al.  Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. , 2003, American journal of physiology. Endocrinology and metabolism.

[11]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[12]  K. Chayama,et al.  Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. , 2002, Journal of the American College of Cardiology.

[13]  J. Ghali.  Race, ethnicity, and heart failure. , 2002, Journal of cardiac failure.

[14]  M. Davies,et al.  Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. , 2002, European heart journal.

[15]  J. Pankow,et al.  Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. , 2002, Journal of the National Medical Association.

[16]  A. Coats.  Omapatrilat--the story of Overture and Octave. , 2002, International journal of cardiology.

[17]  A. Coats,et al.  Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? , 2002, International journal of cardiology.

[18]  G. Lip,et al.  ETHNICITY AND PERIPHERAL VASCULAR DISEASE , 2002, International journal of clinical practice.

[19]  H. Ibsen,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol ☆ , 2002 .

[20]  R. Califf,et al.  Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.

[21]  J. Loscalzo,et al.  Effects of Black Race on Forearm Resistance Vessel Function , 2002, Hypertension.

[22]  Anne L. Taylor,et al.  African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. , 2002, Journal of cardiac failure.

[23]  Simon Capewell,et al.  The current cost of heart failure to the National Health Service in the UK , 2002, European journal of heart failure.

[24]  H. Krumholz,et al.  Differences between African Americans and whites in the outcome of heart failure: Evidence for a greater functional decline in African Americans. , 2002, American heart journal.

[25]  V. Smith,et al.  The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. , 2002, Journal of the American College of Cardiology.

[26]  C. Upshaw.  Reduced prevalence of atrial fibrillation in black patients compared with white patients attending an urban hospital: an electrocardiographic study. , 2002, Journal of the National Medical Association.

[27]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[28]  A. Crook,et al.  Ethnic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography , 2002, BMJ : British Medical Journal.

[29]  S. Verma,et al.  Fundamentals of endothelial function for the clinical cardiologist. , 2002, Circulation.

[30]  G. Lip,et al.  Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation Therapy: The West Birmingham Atrial Fibrillation Project , 2002, Stroke.

[31]  V. Campese,et al.  Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients , 2001, Hypertension.

[32]  R. Lancashire,et al.  Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.

[33]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[34]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[35]  V. Miller,et al.  Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. , 2001, Journal of applied physiology.

[36]  H. Cohen,et al.  Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[37]  M. Pfeffer,et al.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.

[38]  P. Poole‐Wilson,et al.  Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. , 2000, Circulation.

[39]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[40]  T. Lüscher,et al.  Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis. , 2000, Journal of the American Society of Nephrology : JASN.

[41]  G. Mensah,et al.  Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. , 2000, Hypertension.

[42]  G. Lip,et al.  Atrial fibrillation and ethnicity. , 1999, Circulation.

[43]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[44]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[45]  A. Ergul,et al.  Distribution of endothelin receptors in saphenous veins of African Americans: implications of racial differences. , 1999, Journal of cardiovascular pharmacology.

[46]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[47]  D. Tepper.  Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). , 1999, Congestive heart failure.

[48]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[49]  J. Kooner,et al.  Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians , 1999, Heart.

[50]  A. Segev,et al.  The Cardiac Insufficiency Bisoprolol Study II , 1999, The Lancet.

[51]  N. S. Andrawis,et al.  Impaired endothelial‐dependent forearm vascular relaxation in black Americans , 1999, Clinical pharmacology and therapeutics.

[52]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[53]  D. Mant,et al.  Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey , 1999, BMJ.

[54]  R. Cannon,et al.  Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. , 1999, Circulation.

[55]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[56]  A. Ergul,et al.  Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. , 1998, The Journal of pharmacology and experimental therapeutics.

[57]  P. Sanders,et al.  Vascular smooth muscle nitric oxide synthase anomalies in Dahl/Rapp salt-sensitive rats. , 1998, Hypertension.

[58]  M. A. Mahgoub,et al.  Diabetes mellitus and cardiac function , 1998, Molecular and Cellular Biochemistry.

[59]  M. Kukin,et al.  Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. , 1997, The American journal of cardiology.

[60]  H. Eichler,et al.  Effects of endothelin‐1 on circulating adhesion molecules in man , 1997, European journal of clinical investigation.

[61]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[62]  C. Lang,et al.  Sympathoinhibitory response to clonidine is blunted in patients with heart failure. , 1997, Hypertension.

[63]  C. Lang,et al.  Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. , 1997, Hypertension.

[64]  D. Beevers,et al.  ACUTE ADMISSIONS WITH HEART FAILURE TO A DISTRICT GENERAL HOSPITAL SERVING A MULTIRACIAL POPULATION , 1997, International journal of clinical practice.

[65]  J. Sorof,et al.  Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. , 1997, Hypertension.

[66]  A. J. Walker,et al.  Cardiovascular and plasma catecholamine response to static exercise in normotensive blacks and whites. , 1997, Ethnicity & health.

[67]  A. Ergul,et al.  Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. , 1996, Hypertension.

[68]  L. Ghiadoni,et al.  Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. , 1996, Circulation.

[69]  B. Phillips,et al.  Racial and gender differences in endothelin-1. , 1996, The American journal of cardiology.

[70]  Richard S. Cooper,et al.  Is hypertension more severe among U.S. blacks, or is severe hypertension more common? , 1996, Annals of epidemiology.

[71]  C. Lang,et al.  Attenuation of isoproterenol-mediated vasodilatation in blacks. , 1995, The New England journal of medicine.

[72]  P. Ridker,et al.  Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. , 1994, Circulation.

[73]  C. Benedict,et al.  Neurohormones in patients with ischemic left ventricular dysfunction , 1994, Cardiovascular Drugs and Therapy.

[74]  P. Papanek,et al.  Effect of chronic renal medullary nitric oxide inhibition on blood pressure. , 1994, The American journal of physiology.

[75]  P. Sever,et al.  Racial differences in cardiac structure and function in essential hypertension , 1994, BMJ.

[76]  L. Kuller,et al.  Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. , 1994, American journal of epidemiology.

[77]  S. Oparil,et al.  Normotensive blacks have heightened sympathetic response to cold pressor test. , 1993, Hypertension.

[78]  R. Gillum,et al.  Epidemiology of heart failure in the United States. , 1993, American heart journal.

[79]  A. Sherwood,et al.  Responsiveness to α- and β-Adrenergic Receptor Agonists Effects of Race in Borderline Hypertensive Compared to Normotensive Men , 1993 .

[80]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[81]  D J Reda,et al.  Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo , 1993 .

[82]  S. Coughlin,et al.  Black‐White Differences in Idiopathic Dilated Cardiomyopathy: The Washington DC Dilated Cardiomyopathy Study , 1993, Epidemiology.

[83]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[84]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[85]  A. Takeshita,et al.  Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. , 1992, Hypertension.

[86]  P. Sanders,et al.  L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. , 1991, The Journal of clinical investigation.

[87]  T. Rector,et al.  Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure , 1991, Circulation.

[88]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[89]  E. Schiffrin,et al.  Plasma endothelin in human essential hypertension. , 1991, American journal of hypertension.

[90]  J. Sullivan.  Salt Sensitivity Definition, Conception, Methodology, and Long‐term Issues , 1991, Hypertension.

[91]  G. Sutton,et al.  Epidemiologic aspects of heart failure. , 1990, American heart journal.

[92]  K. Swedberg,et al.  Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. , 1990, The American journal of cardiology.

[93]  B. Massie,et al.  A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks , 1990 .

[94]  T. Horio,et al.  Plasma immunoreactive endothelin in essential hypertension. , 1990, The American journal of medicine.

[95]  M. Shichiri,et al.  Plasma endothelin levels in hypertension and chronic renal failure. , 1990, Hypertension.

[96]  M. J. Ashby,et al.  A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. , 1990, Clinical science.

[97]  S. Kilfeather,et al.  Ethnic differences in cyclic AMP accumulation: Effect on α2, β2, and prostanoid receptor responses , 1990 .

[98]  G. Somes,et al.  Race and Gender Influence Ambulatory Blood Pressure Patterns of Adolescents , 1989, Hypertension.

[99]  L. Cardozo,et al.  Racial Differences in Drug Response: Isoproterenol Effects on Heart Rate in Healthy Males , 1989, Pharmaceutical Research.

[100]  W. Kannel.  Epidemiological aspects of heart failure. , 1989, Cardiology clinics.

[101]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[102]  J. Dimsdale,et al.  Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. , 1987, Hypertension.

[103]  J. Cohn,et al.  Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. , 1987, American heart journal.

[104]  L. Cubeddu,et al.  A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. , 1986, JAMA.

[105]  J. Cohn,et al.  The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.

[106]  J. Laragh,et al.  Contrast in cardiac anatomy and function between black and white patients with hypertension. , 1984, Journal of the National Medical Association.

[107]  R. Watson,et al.  Cardiovascular Response in Black and White Hypertensives , 1982, Hypertension.

[108]  T. Meade,et al.  Ethnic group comparisons of variables associated with ischaemic heart disease. , 1978, British heart journal.

[109]  A. Dyer,et al.  Multivariate analysis of the relationship of seven variables to blood pressure: findings of the Chicago Heart Association Detection Project in Industry, 1967-1972. , 1975, Journal of chronic diseases.

[110]  J. Laragh,et al.  Renin as a risk factor in essential hypertension: more evidence. , 1973, The American journal of medicine.

[111]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[112]  T. Diperri,et al.  Aldosterone in congestive heart failure. , 1959, Acta medica Scandinavica.

[113]  N. Abate,et al.  The impact of ethnicity on type 2 diabetes. , 2003, Journal of diabetes and its complications.

[114]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[115]  F. Ruschitzka.  Clinical Trials Report , 2003 .

[116]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[117]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[118]  P. Stolley.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[119]  M. Wolzt,et al.  Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. , 1996, Canadian journal of physiology and pharmacology.

[120]  J. Dimsdale,et al.  Racial differences in epinephrine and beta 2-adrenergic receptors. , 1995, Hypertension.

[121]  J. Dimsdale,et al.  Racial Differences in Epinephrine and β2-Adrenergic Receptors , 1995 .

[122]  L. G. Veasy,et al.  Persistence of acute rheumatic fever in the intermountain area of the United States. , 1994, The Journal of pediatrics.

[123]  G. Bonsel,et al.  Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. , 1994, American journal of public health.

[124]  UK Prospective Diabetes Study XII: Differences Between Asian, Afro‐Caribbean and White Caucasian Type 2 Diabetic Patients at Diagnosis of Diabetes , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[125]  A. Sherwood,et al.  Responsiveness to alpha- and beta-adrenergic receptor agonists. Effects of race in borderline hypertensive compared to normotensive men. , 1993, American journal of hypertension.

[126]  W. J. Plooy,et al.  Differences in lymphocyte beta-2-adrenoceptor density could explain reported differences in basal lymphocyte cAMP production in two ethnic groups , 1993 .

[127]  M. Blaufox,et al.  The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. , 1992, American journal of hypertension.

[128]  A. Sherwood,et al.  High Cardiovascular Reactivity to Stress , 1992 .

[129]  L. Kuller,et al.  CARDIOVASCULAR DISEASES AND STROKE IN AFRICAN-AMERICANS AND OTHER RACIAL MINORITIES IN THE UNITED STATES : A STATEMENT FOR HEALTH PROFESSIONALS , 1991 .

[130]  G. Harshfield,et al.  Circadian variation of blood pressure in blacks: influence of age, gender and activity. , 1990, Journal of human hypertension.

[131]  S. Kilfeather,et al.  Ethnic differences in cyclic AMP accumulation: effect on alpha 2, beta 2, and prostanoid receptor responses. , 1990, Clinical pharmacology and therapeutics.

[132]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[133]  R. Gillum,et al.  Precursors of hypertension in black compared to white medical students. , 1987, Journal of chronic diseases.

[134]  Race, education and prevalence of hypertension. , 1977, American journal of epidemiology.

[135]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .